In a report released today, Jotin Marango from Roth Capital maintained a Hold rating on Savara Inc (SVRA), with a price target of $10. The company’s shares opened today at $11.26.
Marango commented:
“We assign a 15% probability to this outcome, and believe that shares would trade up to high teens. According to our model, full value for Molgradex in PAP is $13/share, which may then be complemented with some additional low single digit dollar value per share attributable to the pipeline (including AeroVanc in CF).”
According to TipRanks.com, Marango is ranked 0 out of 5 stars with an average return of -6.1% and a 38.9% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Syros Pharmaceuticals.
Currently, the analyst consensus on Savara Inc is a Strong Buy with an average price target of $21.67.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.06 and a one-year low of $6.21. Currently, Savara Inc has an average volume of 218K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
